Feb 19,2019

Insulet to Present at Upcoming Investor Conferences

Insulet Corporation (Insulet), the global leader in tubeless insulin pump technology with its Omnipod® Insulin Management System, today announced that management will present at three upcoming investor conferences:

CONFERENCES
View Analyst & Ambassador Comments
Go to original news
Feb 19,2019

PKvitality Continuous Glucose Monitor K’Watch is Exciting

The PKvitality team wants to disrupt the existing CGM market. Rather than making incremental improvements they have reimagined the CGM experience. Their goal is to significantly expand the use of CGM for people with T1D and T2D. The smartwatch-based approach provides a discrete and pain-free solution that keeps any complexity in the watch itself. This enables the sensor to be radically lower in cost.

PRODUCT

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 19,2019

Medtronic Receives FDA Breakthrough Designation for Developing Personalized Closed Loop Insulin Pump System for Diabetes Management

Medtronic plc, the global leader in medical technology, today announced it has received Breakthrough Device designation from the U.S. Food and Drug Administration (FDA) for its Personalized Closed Loop (PCL) insulin pump system, currently in development. The PCL technology is designed to automate insulin delivery in a way that is real-time, personalized and adapts to the user. The system will also provide insights and predictive diagnostics unique to the individual, with a goal of dramatically simplifying diabetes management for the patient. The recent acquisition of Nutrino Health and their expertise in nutrition data science will play a key role in the accelerated development of this breakthrough technology.

REGULATORY FDA

#closed loop

#insulin pump

View Analyst & Ambassador Comments
Go to original news
Feb 20,2019

People With Diabetes Using One Drop & Afrezza Significantly Lower A1c In 3 Months

In a partnership between One Drop and Mannkind, the A-One randomized control trial was conducted to evaluate inhalable insulin and digital therapy among people with type 2 diabetes. Participants were randomized to receive One Drop + Afrezza, or One Drop + their current injectable bolus insulin. All enrolled participants used One Drop's solution (One Drop | Mobile app, One Drop | Chrome glucose meter and testing supplies, and One Drop | Experts coaching) for 3 months and people in the One Drop + Afrezza group received a 3-month supply of Afrezza upon receipt of a prescription. At the end of the study, participants completed a follow-up survey and a lab A1c test.

CLINICAL STUDY

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 20,2019

Tandem Diabetes Care Appoints New Senior Vice President to Drive Expansion of Digital Health and Information Technology Initiatives

Tandem Diabetes Care, Inc., a leading insulin delivery and diabetes technology company, today announced the appointment of Manuel Jaime as its new Senior Vice President, Technology and Digital Health. Jaime will lead all activities related to information technology, data management and security, data analytics, and mobile/connected health solutions.

View Analyst & Ambassador Comments
Go to original news
Feb 20,2019

ABBOTT AND NOVO NORDISK ENTER PARTNERSHIP TO PROVIDE INTEGRATED DIGITAL SOLUTION TO PEOPLE WITH DIABETES USING INSULIN

Abbott and Novo Nordisk today announced a non-exclusive partnership that will integrate insulin dose data from Novo Nordisk pre-filled and durable connected pens directly into the digital health tools compatible with the FreeStyle Libre system (FreeStyle LibreLink mobile app and LibreView cloud-based system). The partnership reflects both companies′ commitment to make diabetes management easier by connecting key technologies such as continuous glucose monitoring (CGM) and connected insulin pens.

COLLABORATION PARTNERSHIP

#connected device

#insulin pen

#mobile app

View Analyst & Ambassador Comments
Go to original news
Feb 21,2019

NEW REAL-WORLD EVIDENCE ANALYSIS OF NEARLY HALF A MILLION FREESTYLE® LIBRE SYSTEM USERS SHOWS HIGHER RATES OF SCANNING IMPROVES GLUCOSE CONTROL

Abbott today announced data from three real-world evidence studies that provide a comprehensive look at the global use of the FreeStyle® Libre flash glucose monitoring system and its impact on health outcomes for people living with diabetes. The new real-world evidence analyses, which for the first time included data from the United States, highlighted key user benefits, including reduction in prolonged hypoglycemia and better glucose control when using both the glucose level and trend arrow during meal times. The data was presented today at the 12th Advanced Technologies & Treatments for Diabetes (ATTD) meeting in Berlin.

CLINICAL STUDY

#cgm

View Analyst & Ambassador Comments
Go to original news
Feb 21,2019

New Virta Health Results Add Improved Sleep as Benefit of the Virta Treatment

Virta Health, the first company with a treatment to safely and sustainably reverse type 2 diabetes (T2D) without the use of medications or surgery, today announced the publication of new peer-reviewed research in Sleep Medicine. This most recent publication found significant improvement in self-reported sleep in type 2 diabetes and prediabetes patients who completed one year of the Virta Treatment.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Feb 21,2019

Cipla and Wellthy Therapeutics Announce Partnership to Offer Digital Therapeutics for Diabetes and Cardiovascular Diseases

Under the agreement, a multi-lingual clinically-validated digital disease management platform will be made available to patients living with diabetes or cardiovascular diseases via doctors' clinics or co-packaging on select Cipla brands. The platform brings together behavioral science, real-world clinical evidence and artificial intelligence to provide real-time monitoring, coaching and advice to patients, and virtual clinical assistance to doctors.

COLLABORATION PARTNERSHIP

#product & service

#dtx

View Analyst & Ambassador Comments
Go to original news
Feb 21,2019

USAGE OF CONTOUR®DIABETES APP SHOWN TO REDUCE THE LIKELIHOOD OF HYPOGLYCEMIC EVENTS IN PEOPLE WITH DIABETES, ACCORDING TO EUROPEAN STUDY PRESENTED AT THE ADVANCED TECHNOLOGY AND TREATMENTS FOR DIABETES MEETING 2019

Today at the 12th International Conference on Advanced Technologies and Treatments for Diabetes (ATTD), Ascensia Diabetes Care has presented clinical research from the first European study to demonstrate that use of the CONTOUR®NEXT ONE blood glucose meter in combination with the CONTOUR®DIABETES app can reduce the likelihood of hypoglycemic events in people with diabetes.

CLINICAL STUDY
View Analyst & Ambassador Comments
Go to original news
Subscribe to DIABETES